Jura Bio introduced VISTA, an AI-controlled data loop system designed to accelerate de novo antibody design for cancer therapeutics. The platform integrates generative modeling, high-throughput synthesis, and functional screening in a closed loop that iteratively refines antibody sequences based on biological activity. Backed by geneticist George Church, Jura combines microfluidics with synthesis automation to generate large-scale functional datasets, addressing the paucity of annotated human translational data critical for AI-driven drug discovery at scale.